Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Takeda Oncology
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
35.0%
+2.8% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:NeutralThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Merck & Co.
Competitor Displacement Rate
18.0%
Competitors are displacing Takeda Oncology in 18.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Takeda Oncology is challenged by Merck's leading immuno-oncology therapies and extensive clinical trial data. Competitors have a stronger pipeline in advanced cancer treatments.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[roche.com][bms.com]⚠️ Identified Vulnerability:Pipeline Strength
Primary Threat Identified:Merck & Co.
Target Persona:Oncologists
🚨 Threat Velocity:6/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)